Published On:October 20, 2016, 1:44 pm
Age-related Macular Degeneration (AMD) is a persistent chronic eye disease which is generally noticed in patients who are above 50 years of age. AMD is more dominant and widespread in the developed nations and is the reason for almost 8.7% of total blindness in the world. AMD causes impairment to macular areas of the eye which hampers an individual’s ability to see and compromises the vision in the core of the retina. Age-related Macular Degeneration is bifurcated into dry macular degeneration and wet macular degeneration. The latter is more severe and it incorporates abnormal growth of blood vessels in the macular area thereby causing harm to the retinal vision. The market of drugs for the treatment of AMD is impelled by several AMD patients across the globe. American Academy of Ophthalmology approximated that 11 million Americans are affected by AMD and the predominance is more in countries among South East Asia and sub-Saharan Africa owing to the Vitamin A Deficiency.
The Global and China Age-related Macular Degeneration Drugs Market is predicted to reach US $90 billion by 2020. According to the research study conducted of the AMD drugs market in China, Japan, India and the U.S – the global market of this industry is approximated to escalate at a CAGR of 6.78% during the forecast period from 2016 to 2021. It also predicts that the market grow from US $64.83 billion in 2015 to US $90 billion by the end of the forecast period. The expeditious worldwide rise in the aged population is the prime reason to fuel the drugs for treatment market of age-related macular degeneration. A study notified that in the United States alone, the total revenue garnered from the sale of these drugs has already reached a whopping US $36.8 billion in 2015.
To Get Sample Copy Of This Report, Click Here: http://www.qyresearchgroups.com/request-sample/68486
It has been observed that the AMD drug for treatment market is overpoweringly prevailed by anti-vascular endothelial growth factor (anti-VEGF) drugs, also including Avastin, Eylea, and Lucentis. Moreover, all of this collectively accounted for 98% of the total sales in 2013. Nonetheless, the dominance of anti-VEGF will take a striking topple post the launch of new adjuvant therapeutics for wet AMD, i.e., squalamine and Fovista; and for dry AMD – emixustat and lampalizumab during the forecast period. A few of the prime market players of this industry are Bayer Healthcare (a subsidiary of Bayer AG), Novartis AG, Genentech, Inc. (a member of Roche Group), Regeneron Pharmaceuticals Inc., Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
We will be happy to help you find what you need. Please write to us: